ArticleJournal of maxillofacial and oral surgery2025
Can Tumor Biomarkers Help in Prognostication of Benign Aggressive Lesions of Maxillofacial Region?
Article in Journal of maxillofacial and oral surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Giant Cell Tumor of Bone: Biology, Pathophysiology, and Histopathology in the Era of H3F3A.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To understand benign aggressive lesions at protein expression level, several tumor biomarkers assist in diagnosis, early detection and nature of the lesion with prognostication. Cell proliferation is the foundation of tumor development. Cyclin D1 and Ki-67 are two proliferation markers. The p53 gene, located at the short arm of chromosome 17 is the best known tumor suppressor gene. In this study, immunohistochemical staining is done to assess the expression patterns of Ki-67, p53 and Cyclin D1 in the benign aggressive lesions of the maxillofacial region and relate it with the clinical, histopathological and radiological expression of the disease. Methods and Results: 15 patients with biopsy proven benign aggressive lesions were enrolled for the present study which included 5 cases each of Odontogenic Keratocyst, Central Giant Cell Granuloma and Ameloblastoma. Analysis of data was done, and relationship with biomarkers was established based on the site, histopathological diagnosis, immunohistochemical expression as percentage cells and intensity and adverse features - cranial nerve involvement, root resorption, mobility of teeth and plate perforation. It was found out in the study that the Ki-67 intensity was significantly associated with root resorption of the teeth and Cyclin D1 immunoexpression was found significantly higher in lesions occurring in the posterior mandible. Discussion: Most of the cases with cyclin D1 score of ≤ 50% occurred in the posterior mandible which signifies the overexpression of cyclin D1 contributes to increased proliferative activity and tumor invasiveness. Ki-67 intensity showed a significant correlation with root resorption of teeth suggesting the role of Ki-67 as a proliferative marker in benign aggressive lesions. Conclusion: Elevated levels of biomarkers point toward a more aggressive lesion thereby necessitating a more aggressive treatment approach. Benign aggressive lesions can express various tumor biomarkers which help the surgeon in formulating the treatment plan and predict the prognosis of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.